Trial Profile
Study of 8-Week Glecaprevir/ Pibrentasvir (G/P) for Treatment Naive, Non- Cirrhotic Patients with HCV Infection in the Trio Health Network
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Apr 2020
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 11 Apr 2020 Results (n=73) assessing efficacy of Glecaprevir/ Pibrentasvir in Hepatitis C patients, published in the Advances in Therapy
- 13 Dec 2018 New trial record
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases